论文部分内容阅读
[目的]探讨经导管肋间动脉灌注化疗治疗肋骨转移瘤的临床疗效。[方法]对17例25个肋骨转移瘤行经导管肋间动脉灌注化疗,随访观察3～22个月,分析总结临床疗效及其并发症。[结果]25个肋骨转移瘤经治疗后疼痛缓解程度按VAS评分:完全缓解(CR)11个,部分缓解(PR)12个,轻度缓解(MR)2个,总有效率100%。肿块缩小,生命质量改善,血管造影见肿瘤血管和肿瘤染色明显减少,影像学检查见软组织肿块缩小,骨破坏减缓及新骨生成,无严重并发症发生。[结论]经导管肋间动脉灌注化疗是治疗肋骨转移瘤的一种安全、有效的姑息疗法,对缓解疼痛、提高生命质量具有重要的临床意义。
[Objective] To investigate the clinical efficacy of transcathectic intercostal arterial infusion chemotherapy for rib metastases. [Method] Twenty-five patients with 25 rib metastases underwent intercostal intercostal arterial infusion chemotherapy. The patients were followed up for 3 to 22 months. The clinical efficacy and complications were analyzed. [Results] The pain relief degree of 25 rib metastases was VAS according to VAS score: 11 for complete remission (CR), 12 for partial remission (PR) and 2 for mild remission (MR). The total effective rate was 100%. The mass of the tumor was reduced and the quality of life improved. The number of blood vessels and tumors in the tumor angiography was significantly reduced. The soft tissue mass was reduced, the bone destruction was slowed and the formation of new bone was seen in the imaging examination. No serious complications occurred. [Conclusion] Transcatheter intercostal arterial infusion chemotherapy is a safe and effective palliative treatment for rib metastases, which has important clinical significance in relieving pain and improving quality of life.